Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor
Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
In Reply: In response to Drs Silverstein and
Tagliente, because Shammash et al1 did not
separate patients who had long-term β-blockers discontinued from those
who had perioperative β-blockers discontinued, it is indeed unclear what
led to mortality in their findings. For example, it is possible that the excess
mortality they observed was a result of so-called rebound from β-blockers,
removal of the protective effect of perioperatively administered β-blockers,
or withdrawal of the protective effect of chronically administered β-blockers.
Auerbach AD, Goldman L. When Should Perioperative β-Blockers Be Discontinued?—Reply. JAMA. 2002;287(23):3079-3080. doi:10.1001/jama.287.23.3077